NCT00740805View on ClinicalTrials.gov

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 18, 2008

Primary Completion Date

September 3, 2021

Study Completion Date

October 22, 2025

Conditions

Ann Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaSolid Neoplasm

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given PO

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00740805 - Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter